News
INVO Bioscience and idsMED Group Enter Distribution Agreement for Malaysia
- Malaysia represents a significant addressable market opportunity with approximately 10% of the population suffering from infertility.- idsMED is one of the largest and most well-respected medical solutions providers in the region.- Product registration is already...
INVO Bioscience Forms Scientific Advisory Board with Leaders from Fertility Industry
SARASOTA, Fla., Nov. 18, 2020 -- INVO Bioscience, Inc. (Nasdaq: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the formation of its Scientific Advisory Board (SAB) with the appointment of several prominent...
INVO Bioscience Reports Third Quarter 2020 Financial Results
Company to Provide Investor Update on November 19 at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 16, 2020 -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and...
INVO Bioscience Establishes Joint Venture to Operate Dedicated INVOcell Fertility Clinics in Mexico
Joint Venture Targets the Large and Growing Mexico Market for Infertility ServicesSARASOTA, Fla., Sept. 30, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today it has teamed up...
INVO Bioscience Announces Appointment of Barbara Ryan and Matthew Szot to the Board of Directors
INVO's Board strengthened with independent directors as we enter a new growth trajectory for the CompanySARASOTA, Fla., Sept. 16, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed...
INVO Bioscience Reports Second Quarter 2020 Financial Results
Company to Provide Investor Update During Virtual Investor Conference on August 19 at 2:00pm ET (Details Below); Management Available for Virtual 1x1 MeetingsSARASOTA, Fla., Aug. 13, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on...
INVO Bioscience to Present at the August 2020 Lytham Partners Virtual Investor Growth Conference
SARASOTA, Fla., Aug. 6, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company", "INVO") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo...
INVO Bioscience Receives Registration Approval for INVOcell in Turkey
- An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving- "As the world's only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility...
America Institute for Reproductive Medicine of Birmingham Alabama (“AIRM”) Spotlights its Success in the Use of INVOcell
- According to AIRM, "IVF with INVOcell is a simple, cost-effective, and highly rewarding methodology to increase access to care for assisted reproduction"- Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are...
INVO Bioscience Announces Closing of Financing
SARASOTA, Fla., June 29, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,...